
Cingulate shares plans to resubmit its ADHD candidate CTx-1301 to the FDA, following a CRL tied to CMC information requests
A new combination of subjective and objective measures might finally provide a reliable answer.
It can be difficult to know if treatments for attention-deficit/hyperactivity disorder are having the desired effects. This is in part because clinical procedures commonly rely on self-rated scales and interviews. Could a more objective measurement be added into the mix?
In this Mental Health Minute, Dr Roy discusses the results of
Dr Roy is board certified in internal medicine and pediatrics. He specializes in treating ADHD.